Definition/Introduction
Symptothermal contraception or fertility awareness-based methods (FABMs) of family planning are birth control methods in which women collect information to inform themselves of their fertile window, the days of the cycle with the highest fecundity.[1] These methods depend on observations of signs and symptoms that correlate with different hormone levels as indicators for an approximate timeframe when ovulation is likely to occur. Typical data may include 1 or more of the following: menstrual dates, basal body temperature (BBT), cervical mucus or position, and urinary hormone metabolites.[1] Due to the data collection that the patient requires, symptothermal contraception is commonly referred to as a "fertility-awareness" contraceptive method.[2] FABMs of family planning incorporate barrier methods, such as condoms, spermicidal gel, diaphragms, and withdrawal use during the fertile window. The use of these barriers distinguishes FABMs of family planning from natural family planning, which allows only abstinence during the fertile days.[3]
Most women experience an increase in their BBT of 0.5°F (0.3°C) shortly after ovulation. This increase in temperature is due to an increase in the release of both progesterone and estrogen by the corpus luteum during the luteal phase of the menstrual cycle. This increase in temperature persists until 1 to 2 days prior to menstruation.[3][4] The most fertile days of the cycle are the 2 to 3 days before this increase in temperature, during which ovulation most likely occurs.[5] A thermal nadir, the lowest BBT of the cycle, typically occurs the day before ovulation. Once BBT has persistently increased, ovulation has occurred, and the fertile window is over.[3] BBT is defined as the lowest natural body temperature recorded after a period of rest in the absence of pathology. The individual measures their BBT with a thermometer every morning upon awakening. The temperature must be recorded at approximately the same time each day.[6] The fertile windows can also be predicted based on algorithmic calculations from previous cycles.[3] The woman may prevent conception by avoiding sexual intercourse or using a barrier method during this time period.[7] Women are recommended to abstain from sexual intercourse 2 to 3 days prior to the expected increase in their body temperature and up to 3 days after its initial increase. The male partner's role in the FABMs of contraception cannot be overlooked since abstinence and condom or other barrier use are necessary for these methods to be effective.[3]
The person may also evaluate their cervical mucus or fluid (secretions) and its texture, consistency, and color daily. Adding a sign of estrogenic activity, like cervical mucus or urinary estrogen metabolites, increases the accuracy of identifying the fertile window compared to BBT measurements alone.[8] Cervical mucus either promotes or prohibits the passage of sperm during various times of the menstrual cycle.[3] At the beginning of the menstrual cycle, cervical mucus is tacky or viscid in nature. During the fertile period of the menstrual cycle, the cervical mucus is clear, abundant, and stretchy. This consistency of cervical mucus is present only during the fertile window.[3] It can be stretched between 2 fingers to a length of at least 6 cm due to an increase in estrogen at the end of the follicular phase.[9] This mucus consistency is meant to facilitate sperm mobilization for the process of fertilization. The aforementioned changes in cervical mucus can be detected approximately 4 to 7 days before ovulation.[4]
To reliably predict the upcoming menstrual cycles, it has been suggested that data collection should be done for approximately 6 to 12 cycles.[9] Using all of this information, the woman may then chart her menstrual cycle and determine which days they are in the luteal phase, the follicular phase, and which day ovulation is most likely to occur. The woman may then be able to determine their "fertile window," which is the period of days around ovulation when conception is most likely to occur.[10] The ovum remains able to be fertilized for 12 to 24 hours after ovulation. Sperm can live for up to 5 days after deposition in the female genital tract. These 2 considerations result in a fertile window of approximately 6 days. The highest chance of achieving pregnancy occurs in the 2 days before ovulation. Since a person does not usually ovulate on the same day with every cycle, the fertile window is considered to be longer than the actual 6 days with the FABMs of contraception.[3]
Tracking menstrual cycle length is another component that may be used in FABMs of contraception. Ovulation occurs 9 to 16 days prior to the end of a menstrual cycle. For example, in a person who has menstrual cycles that range from 26 to 32 days in length, the fertile window is likely to be days 8 through 19.[3] By tracking urinary hormones, specifically luteinizing hormone, and possibly estradiol, progesterone, and pregnanediol glucuronide, the completion of the fertile window may be appreciated. However, these urinary tests may not help predict the beginning of the fertile window.[3]
Many fertility-tracking apps have become popular for use in tracking cycles for people using symptothermal contraception. These apps help to identify the fertile window in order to avoid pregnancy. However, several reviews have found that these apps have not successfully predicted the fertile window and little evidence-based research supports their use. Many of these fertility-tracking apps have not been shown to be successful in pregnancy prevention. Additionally, when a comparison was made between apps, there was a large variation in the fertile window start day and fertile window end day for a specific patient's data. Furthermore, many apps failed to identify all days that likely fall within the physiologically fertile window. A study of 40 apps and technologies found that only 4 could effectively predict fertility windows. Therefore, patients may experience unintended pregnancies because they are unknowingly relying on technology that is not evidence-based.[8]
Issues of Concern
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Issues of Concern
The effectiveness rate of using the symptothermal method as a means of preventing unplanned pregnancy is controversial and highly debated. Multiple sources and studies report differing results. An observational longitudinal cohort study conducted in Germany in 1985 reported a pregnancy rate of 0.6 per 100 subjects after recording 13 cycles among 900 subjects. Each of these subjects denied sexual intercourse during their fertile period.[11] Data collected from patients who did not strictly adhere to abstinence from intercourse during their fertile period was eliminated from the study.
Results from another study across 5 nations by the World Health Organization (WHO) published in 1981 reported a method-related pregnancy rate of 2.8%. However, the overall pregnancy rate of patients using the method was 22.6%.[4] About 19.6% of the patients' pregnancies were due to user-related errors during the implementation of the method. More recent data has shown typical use pregnancy rates ranging from 1.8% to 33.6% and 0.4% to 12.1% for perfect use rates. The large variation in pregnancy rates is due to a variety of FABMs of contraception that are available and a limited number of people utilizing 1 specific method.[3]
The main risk associated with this contraceptive method is the failure to prevent conception due to errors in instruction, the method's application, failure to abstain or use a barrier method during the fertile period, and unreliable data collection.[12] The primary reason for this method's failure in preventing conception is the inappropriate implementation or lack of patient education. The presence of pathology causing an increase in body temperature, such as a fever, is also an issue of concern relative to data collection. Women who experience inconsistent menstrual cycles may also have difficulty using this method of contraception.
Clinical Significance
The number of patients using symptothermal contraception as their primary birth control method has steadily increased by an average of 3% to 4% since the 1970s.[13] The wide availability of smartphone apps that help women track data related to their menstrual cycle has contributed to their growing popularity.[14] Wearable devices to track BBT and even cervical mucus are examples of such advancing technology that may increase the ease of use of FABMs.[3] Certain religious groups also strongly encourage their patrons to implement this method as a primary means of contraception.[15] Many people believe they are using an effective FABM of contraception when, in reality, some of these methods have not undergone standard effectiveness evaluations.[1]
The advantages of FABMs include that they are non-hormonal. Additionally, the education needed to use these methods helps people understand their bodies better and may help achieve pregnancy later in life when this is desired. Disadvantages of FABMs include that they require a cooperative partner and pathologic conditions may alter physiology, thus making identifying factors difficult to acknowledge. Recent birth and lactation also make FABMs challenging to use.[3]
Appropriate patient education is absolutely critical for these methods to be successful. Therefore, clinicians need to be very knowledgeable and skilled in counseling women about these and all contraceptive options. Unfortunately, FABMs are not frequently included in contraception counseling sessions, mainly because of the lack of provider guidance and misperceptions of the lack of efficacy.[3] The effectiveness of a particular method in preventing pregnancy may not apply to the specific patient, and the effectiveness rates cannot be definitively compared between methods.[1]
Nursing, Allied Health, and Interprofessional Team Interventions
A collaborative, interprofessional team committed to delivering comprehensive family planning and contraceptive care is pivotal in enhancing patient outcomes. When a patient seeks to chart a course for their fertility journey, whether aspiring to conceive or prevent pregnancy, it is imperative to engage in consultations with skilled physicians and nurses. These healthcare professionals offer invaluable guidance, counseling, and the ability to facilitate necessary referrals. An interprofessional team can adeptly address any challenges that may arise in a patient's quest to access birth control and essential primary health care, all aimed at optimizing their fertility plan.
To achieve optimal patient outcomes, it is essential to prioritize collaboration, shared decision-making, and effective communication. The gold standard of care, guided by an integrated care pathway and evidence-based methodologies, should be centered around women's needs. Women should be equipped with comprehensive written resources detailing the array of contraceptive options available. Moreover, the interprofessional team bears the responsibility of providing unwavering support to women and their families as they navigate the decision-making process to identify the most suitable contraceptive method. In the realm of patient-centered care, it is imperative to honor and respect the preferences, beliefs, and values of women and their families when making choices regarding contraception methods.
References
Peragallo Urrutia R, Polis CB, Jensen ET, Greene ME, Kennedy E, Stanford JB. Effectiveness of Fertility Awareness-Based Methods for Pregnancy Prevention: A Systematic Review. Obstetrics and gynecology. 2018 Sep:132(3):591-604. doi: 10.1097/AOG.0000000000002784. Epub [PubMed PMID: 30095777]
Level 1 (high-level) evidenceSteward K, Raja A. Physiology, Ovulation And Basal Body Temperature. StatPearls. 2023 Jan:(): [PubMed PMID: 31536292]
Simmons RG, Jennings V. Fertility awareness-based methods of family planning. Best practice & research. Clinical obstetrics & gynaecology. 2020 Jul:66():68-82. doi: 10.1016/j.bpobgyn.2019.12.003. Epub 2019 Dec 20 [PubMed PMID: 32169418]
Gallagher J. More about natural family planning. Australian family physician. 1983 Nov:12(11):786-92 [PubMed PMID: 6667188]
Parenteau-Carreau S, Infante-Rivard C. Self-palpation to assess cervical changes in relation to mucus and temperature. International journal of fertility. 1988:33 Suppl():10-6 [PubMed PMID: 2902020]
Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. Endotext. 2000:(): [PubMed PMID: 25905282]
Parenteau-carreau S. [The sympto-thermal methods]. Contraception, fertilite, sexualite. 1983 Nov:11(11):1189-203 [PubMed PMID: 12312702]
Manhart MD, Duane M. A comparison of app-defined fertile days from two fertility tracking apps using identical cycle data. Contraception. 2022 Nov:115():12-16. doi: 10.1016/j.contraception.2022.07.007. Epub 2022 Jul 25 [PubMed PMID: 35901971]
Davis MS. Natural family planning. NAACOG's clinical issues in perinatal and women's health nursing. 1992:3(2):280-90 [PubMed PMID: 1596436]
Frank-Herrmann P, Gnoth C, Baur S, Strowitzki T, Freundl G. Determination of the fertile window: reproductive competence of women--European cycle databases. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2005 Jun:20(6):305-12 [PubMed PMID: 16019378]
Level 2 (mid-level) evidenceFrank-Herrmann P, Heil J, Gnoth C, Toledo E, Baur S, Pyper C, Jenetzky E, Strowitzki T, Freundl G. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple's sexual behaviour during the fertile time: a prospective longitudinal study. Human reproduction (Oxford, England). 2007 May:22(5):1310-9 [PubMed PMID: 17314078]
Zufferey MM. [The risks of the natural family planning methods]. Therapeutische Umschau. Revue therapeutique. 1986 May:43(5):417-24 [PubMed PMID: 3726778]
Klaus H. Natural family planning: a review. Obstetrical & gynecological survey. 1982 Feb:37(2):128-50 [PubMed PMID: 7033851]
Level 3 (low-level) evidenceFreis A, Freundl-Schütt T, Wallwiener LM, Baur S, Strowitzki T, Freundl G, Frank-Herrmann P. Plausibility of Menstrual Cycle Apps Claiming to Support Conception. Frontiers in public health. 2018:6():98. doi: 10.3389/fpubh.2018.00098. Epub 2018 Apr 3 [PubMed PMID: 29666788]
Ryder RE. "Natural family planning": effective birth control supported by the Catholic Church. BMJ (Clinical research ed.). 1993 Sep 18:307(6906):723-6 [PubMed PMID: 8401097]